At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 167 enrolled
Drug / intervention
Daclatasvir +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Antiviral Activity and Safety, Tolerability, and Pharmacokinetics of Daclatasvir in Subjects Infected With Hepatitis C Virus Genotype 1
In Brief
A Phase 2 clinical trial evaluating Daclatasvir and Placebo for Chronic Hepatitis C. Completed, enrolled 167 participants across 8 sites in 2 countries.
Detailed Summary
The primary purpose of this study is to assess the change in Hepatitis C Virus RNA during dosing with daclatasvir and during the follow-up period in subjects with chronic hepatitis C infection
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis C
CountriesPuerto Rico, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 2008
Enrollment StartMay 2008
Primary CompletionJun 2009
TodayJul 2026
First PostedApr 22, 2008
Enrollment StartMay 1, 2008
Primary CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 18.2 years ago
Interventions
Daclatasvirdrug
Capsule, Oral, Approximately 182 days from initial dosing
Placebodrug
Capsule, Oral, After 28 days from initial dosing and unblinding of the dose panel